Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 3/20 | 0.48 |
| ▸ | PGR | P06401 | 2/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12086345 | 0.71 | NR3C2 (0.55) | NR3C1PGRNR3C2GFERKMT2A | |
| SCHEMBL14375100 | 0.70 | SLC12A2 (0.52) | KMT2AALDH1A1TSHR | |
| SCHEMBL6184898 | 0.70 | NR3C1 (0.57) | NR3C1PGRNR3C2GFERKMT2A | |
| SCHEMBL8274390 | 0.69 | CHRNB2 (0.37) | CHRNB2CHRNA5CHRNB4CHRNA3 | |
| SCHEMBL809706 | 0.69 | KMT2A (0.33) | KMT2AALDH1A1TSHRCHRNB2CHRNB4 | |
| SCHEMBL13247696 | 0.69 | KMT2A (0.33) | KMT2AALDH1A1TSHRCHRNB2CHRNB4 | |
| SCHEMBL809853 | 0.69 | KMT2A (0.33) | KMT2AALDH1A1TSHRCHRNB2CHRNB4 | |
| SCHEMBL16508906 | 0.68 | NR3C2 (0.52) | NR3C1PGRNR3C2GFERKMT2A | |
| Hydrochloric Acid SCHEMBL4740768 | 0.68 | KMT2A (0.36) | KMT2ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL14102431 | 0.68 | GBA1 (0.42) | KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP7 | NR3C1 2206/4885PGR 1615/4885NR3C2 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.